Impact of Immunosenescence on Immune-Related Adverse Events in Elderly Patients With Cancer

Overview

Journal Aging Med (Milton)

Specialty Geriatrics

Date 2025 Feb 27

PMID 40012861

Authors

Jiayi Gao

Yue Yuan

Xue Wang

Liuer He

Lin Li

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICI), have transformed the management of several types of cancers; however, immune-related adverse events (irAEs) may cause treatment interruptions, chronic toxic effects, and death. Elderly patients are at high risk of cancer. Compared with traditional chemotherapy, immunotherapy has become a better alternative choice for elderly patients with cancer due to its high efficiency and low toxicity. However, the emergence of immunosenescence accompanied by advancing age raises safety concerns for ICI. Therefore, we summarize the characteristics of irAEs occurred in elderly patients with cancer and the physiological characteristics of immunosenescence, which will lay a theoretical foundation for the safety management of immunotherapy in elderly patients with cancer.

References

Gomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J . A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study. ESMO Open. 2021; 6(1):100042. PMC: 7844568. DOI: 10.1016/j.esmoop.2020.100042. View

Atchley W, Alvarez C, Saxena-Beem S, Schwartz T, Ishizawar R, Patel K . Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021; 160(2):731-742. PMC: 8411447. DOI: 10.1016/j.chest.2021.02.032. View

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro Jr G, Reck M . Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019; 135:188-195. DOI: 10.1016/j.lungcan.2019.07.004. View

Baldini C, Martin Romano P, Voisin A, Danlos F, Champiat S, Laghouati S . Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur J Cancer. 2020; 129:71-79. DOI: 10.1016/j.ejca.2020.01.013. View

Gao J, Zhang P, Tang M, Nie X, Yuan Y, Yang F . Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis. J Cancer Res Clin Oncol. 2023; 149(11):8993-9006. DOI: 10.1007/s00432-023-04792-1. View

Muchnik E, Loh K, Strawderman M, Magnuson A, Mohile S, Estrah V . Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. J Am Geriatr Soc. 2019; 67(5):905-912. PMC: 7814272. DOI: 10.1111/jgs.15750. View

Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A . Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 2021; 161:26-33. DOI: 10.1016/j.lungcan.2021.08.015. View

Gullo G, Rubatto M, Fava P, Brizio M, Tonella L, Ribero S . Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Dermatol Ther. 2022; 35(6):e15492. PMC: 9287008. DOI: 10.1111/dth.15492. View

Samani A, Zhang S, Spiers L, Suwaidan A, Merrick S, Tippu Z . Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer. 2020; 8(2). PMC: 7545628. DOI: 10.1136/jitc-2020-000871. View

10.

Ksienski D, Wai E, Croteau N, Freeman A, Chan A, Fiorino L . Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. J Geriatr Oncol. 2020; 11(5):807-813. DOI: 10.1016/j.jgo.2020.01.006. View

11.

Nebhan C, Cortellini A, Ma W, Ganta T, Song H, Ye F . Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021; 7(12):1856-1861. PMC: 8569601. DOI: 10.1001/jamaoncol.2021.4960. View

12.

Girard N, Bar J, Garrido P, Garassino M, McDonald F, Mornex F . Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2022; 18(2):181-193. DOI: 10.1016/j.jtho.2022.10.003. View

13.

Darwin A, Skinner A, Reed D, Tanvetyanon T . Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly. J Adolesc Young Adult Oncol. 2022; 11(6):550-555. DOI: 10.1089/jayao.2021.0180. View

14.

Zhu H, Galdos F, Lee D, Waliany S, Huang Y, Ryan J . Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation. 2022; 146(4):316-335. PMC: 9397491. DOI: 10.1161/CIRCULATIONAHA.121.056730. View

15.

Bruijnen C, Koldenhof J, Verheijden R, van den Bos F, Emmelot-Vonk M, Witteveen P . Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer. 2022; 128(14):2746-2752. PMC: 9325486. DOI: 10.1002/cncr.34230. View

16.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A . Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018; 95:68-74. DOI: 10.1016/j.ejca.2018.03.002. View